---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Long-term morbidity"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Long-term morbidity. Topics: Usual blood pressure and vascular mortality: one million adults, Excess risk in resistant hypertension: guideline statements, Excess risk in resistant hypertension: Kaiser Permanente Southern California cohort, Excess risk in resistant hypertension: incident treated hypertension cohort, and 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Usual blood pressure and vascular mortality: one million adults

> “Information was obtained on each of one million adults with no previous vascular disease recorded at baseline in 61 prospective observational studies of blood pressure and mortality.”
> “At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes.”

Source: [Lewington et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12493255/)

> “Higher BP is associated with an elevated risk for total CVD, coronary heart disease, HF, aortic and peripheral vascular disease, kidney disease, ischemic and hemorrhagic stroke, dementia, and cognitive impairment.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.7-2"></a>

### Excess risk in resistant hypertension: guideline statements

> “Patients with resistant hypertension are known to have at least a 50% higher risk of MI, stroke, end-stage kidney disease, and cardiovascular death than adults with hypertension without resistance to treatment.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Compared with treated patients who achieve BP control, patients with resistant hypertension (by any definition) have a worse prognosis: risk of myocardial infarction, stroke, end-stage renal disease, and death in these adults may be two- to six-fold higher.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.1.7-3"></a>

### Excess risk in resistant hypertension: Kaiser Permanente Southern California cohort

> “We sought to compare the risk of end stage renal disease (ESRD), ischemic heart event (IHE), congestive heart failure (CHF), cerebrovascular accident (CVA), and all-cause mortality among 470,386 individuals with resistant and nonresistant hypertension (non-RH).”
> “Resistant hypertension (cRH and uRH) compared to non-RH, had multivariable adjusted hazard ratios (95% confidence intervals) of 1.32 (1.27–1.37), 1.24 (1.20–1.28), 1.46 (1.40–1.52), 1.14 (1.10–1.19), and 1.06 (1.03–1.08) for ESRD, IHE, CHF, CVA, and mortality, respectively.”
> “The risk of ESRD and CVA and were 25% and 23% greater, respectively, in uRH compared to cRH supporting the linkage between blood pressure and both outcomes.”

Source: [Sim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4556588/)

<a id="topic-2.2.1.7-4"></a>

### Excess risk in resistant hypertension: incident treated hypertension cohort

> “Following multivariable adjustment including baseline patient demographics, comorbidities, study site, and year of study entry, resistant hypertension was associated with increased risk of adverse CV outcomes (HR 1.47, 95% CI 1.33–1.62, p<0.001).”

Source: [Daugherty et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/)

<a id="topic-2.2.1.7-5"></a>

### Excess risk in uncontrolled and true resistant hypertension

> “Prospective studies using ABPM have suggested an almost 2-fold increased risk of CVD events in patients with true RH compared with those with hypertension responsive to treatment.”
> “In the REGARDS study (Reasons for Geographic and Racial Differences in Stroke), uncontrolled RH was associated with a 2-fold increased risk of coronary heart disease compared with controlled RH.”
> “BP control reduced the risk of incident stroke, coronary heart disease, or heart failure by 13% among those with RH compared with a 31% lower risk of these outcomes among patients without RH.”
> “In patients with CKD, RH is associated with higher risk of myocardial infarction, stroke, peripheral arterial disease, heart failure, and all-cause mortality compared with patients without RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.7-6"></a>

### Excess risk in primary aldosteronism

> “We identified 31 studies including 3838 patients with primary aldosteronism and 9284 patients with essential hypertension.”
> “After a median of 8·8 years (IQR 6·2-10·7) from the diagnosis of hypertension, compared with patients with essential hypertension, patients with primary aldosteronism had an increased risk of stroke (odds ratio [OR] 2·58, 95% CI 1·93-3·45), coronary artery disease (1·77, 1·10-2·83), atrial fibrillation (3·52, 2·06-5·99), and heart failure (2·05, 1·11-3·78).”

Source: [Monticone et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29129575/)

> “Meta-analyses of studies that matched patients with primary aldosteronism to those with primary hypertension showed that primary aldosteronism carries a 2.0-fold increased risk of HF, 2.8-fold increased risk of stroke, 1.7-fold increased risk of coronary artery disease, 4.0-fold increased risk of AF, and increased kidney damage compared with primary hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.7-7"></a>

### Cardiovascular risk reduction per 5 mm Hg systolic blood pressure: individual participant data meta-analysis

> “Data for 344 716 participants from 48 randomised clinical trials were available for this analysis.”
> “In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.”
> “On average, a 5 mm Hg reduction of systolic blood pressure reduced the risk of a major cardiovascular event by about 10%; the corresponding proportional risk reductions for stroke, heart failure, ischaemic heart disease, and cardiovascular death were 13%, 13%, 8%, and 5%, respectively.”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-2.2.1.7-8"></a>

### Cardiovascular risk reduction per 10 mm Hg systolic blood pressure: trial-level meta-analysis

> “We identified 123 studies with 613,815 participants for the tabular meta-analysis.”
> “Every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk of major cardiovascular disease events (relative risk [RR] 0·80, 95% CI 0·77-0·83), coronary heart disease (0·83, 0·78-0·88), stroke (0·73, 0·68-0·77), and heart failure (0·72, 0·67-0·78), which, in the populations studied, led to a significant 13% reduction in all-cause mortality (0·87, 0·84-0·91).”
> “However, the effect on renal failure was not significant (0·95, 0·84-1·07).”
> “There was no clear evidence that proportional risk reductions in major cardiovascular disease differed by baseline disease history, except for diabetes and chronic kidney disease, for which smaller, but significant, risk reductions were detected.”

Source: [Ettehad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26724178/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
